Tapimmune - TPIV

Tapimmune (TPIV)
Coverage: January 21, 2010 - March 21, 2010
Featured: January 21, 2010

Latest Newsletter Editions

Sat, May 22, 2010 @ 02:05 pm
There was a little relief rally on Friday after a fairly wicked week in the markets. Thursday's giant sell down felt like a "cash at any cost" down draft, with almost no regard for value. That's fine with me. These kinds of emotional, momentum driven markets present opportunities for those with the...
Tue, May 18, 2010 @ 10:05 am
A Busy Day- Comments on a Bunch of Stuff Frankly, it's a bit annoying. I wish these smaller companies could get their quarterly numbers out over a few week period in time, instead of all in one or two days at the absolute deadline. I just can't get quality commentary out fast enough for investors to...
Mon, Feb 1, 2010 @ 03:02 pm
Nothing Like a Cool $200 Million You might wonder who's got the cool $200 million, and what it has to do with today's edition of the OTC Journal. Remember my short term trading idea?- TapImmune (OTC BB: TPIV) I said some positive developments would start to roll their way, and today's post close news...
Wed, Jan 27, 2010 @ 09:01 am
Two Beat Downs; Stand By I just wanted to publish a couple of quick notes on two stocks I've been covering and have made comments on recently. First on China Recycling Energy (CREG)- someone is selling the stock fairly ruthlessly with little regard for price. It started two days ago, and the stock is...
Thu, Jan 21, 2010 @ 01:01 pm
How The Immune System Fights Disease Our bodies have a miraculous capability. Our Immune System, through a complex network of cells and chemicals, has the ability to identify bad stuff and rapidly recruit an army to attack foreign invaders and kill them. T-Cells are the circus ring masters. The T-Cells...


Latest Blog Entries


Quote Data

Last Trade: Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: Bid x Ask Size:
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.0000 52wk Range: 0.00 - 0.00
Open: 0.0000 P/E (ttm):
Volume: 0 EPS (ttm):
spacer [Chart]

Business Summary

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.


MarketByte LLC has purchased 400,000 shares of Tapimmune with a cost basis of 7.5 cents from a non affiliate shareholder. The shares are freely tradeable. This should be construed as a form of compensation and a conflict of interest. The aforementioned shares could be sold at anytime without prior notification.

Recent News Headlines

TapImmune Provides Update on PolyStartâ„¢ Vaccine Platform Applicable to Cancer and Infectious Disease
Wed, 22 Oct 2014 14:35:40 GMT
[at noodls] - 22 Oct Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox. ... This is an abstract of the ...
TapImmune Provides Update on PolyStartâ„¢ Vaccine Platform Applicable to Cancer and Infectious Disease
Wed, 22 Oct 2014 12:30:00 GMT
[Business Wire] - TapImmune, Inc. , provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
Tapimmune, a Biotech Company Focused on Stimulating the Body’s Own Immune System to Fight Cancer
Wed, 15 Oct 2014 16:27:26 GMT
[at noodls] - Tapimmune, a Biotech Company Focused on Stimulating the Body's Own Immune System to Fight Cancer TapImmune, a biotech company focused on stimulating the body's own immune system to fight cancer. Please ...
TapImmune CEO Provides Update on Corporate Activity and Progression of Clinical Programs
Tue, 23 Sep 2014 14:47:00 GMT
[Business Wire] - TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.
This 'Game-Changing Stock' Is Working To Cure Cancer
Thu, 18 Sep 2014 18:30:00 GMT
Does TapImmune Have What It Takes To Succeed?
Thu, 18 Sep 2014 14:30:00 GMT
SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data
Thu, 18 Sep 2014 13:00:00 GMT
[Accesswire] - SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor ...
TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Tue, 16 Sep 2014 12:30:00 GMT
[Business Wire] - TapImmune Inc. is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes.
SeeThruEquity to Hold Fall Microcap Investor Conference September 11, 2014
Mon, 08 Sep 2014 13:05:00 GMT
[Accesswire] - Conference Being Held at Convene Times Square in Midtown NEW YORK / ACCESSWIRE / September 8, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused ...
TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
Thu, 04 Sep 2014 13:00:00 GMT
[Accesswire] - Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday ...
TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
Wed, 03 Sep 2014 14:41:00 GMT
[Accesswire] - Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics ...
Tue, 26 Aug 2014 17:04:27 GMT
SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
Tue, 19 Aug 2014 12:50:00 GMT
[Accesswire] - New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has ...
TAPIMMUNE INC Files SEC form 10-Q, Quarterly Report
Mon, 18 Aug 2014 19:41:22 GMT
TAPIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
Thu, 14 Aug 2014 16:45:01 GMT
TapImmune, Inc. Announces $2 Million Registered Direct Offering
Mon, 11 Aug 2014 16:21:00 GMT
[Business Wire] - TapImmune, Inc. , , today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $
TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Thu, 07 Aug 2014 13:23:00 GMT
[Business Wire] - TapImmune Inc. is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN.
TapImmune Prevails in Legal Dispute with Michael Gardner
Thu, 24 Jul 2014 13:38:00 GMT
[Business Wire] - TapImmune Inc. , announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
TAPIMMUNE INC Files SEC form 8-K, Other Events
Wed, 23 Jul 2014 18:31:33 GMT
New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
Wed, 23 Jul 2014 12:01:00 GMT
[Accesswire] - Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company’s scientific advisory board. TapImmune, ...